Burlington Coat Factory Launches Annual Campaign to Support LLS

Burlington Coat Factory has launched its 11th year as a major supporter of the Leukemia & Lymphoma Society (LLS) with its company-wide initiative that encourages their customers to buy small paper balloon icons, the proceeds of which go towards the supporting the LLS.

Since first teaming up with the LLS, Burlington Coat Factory has raised almost $13 million over the previous ten years.

The company's fundraising campaign runs from 9 July 2012 through 29 October 2012 and occurs at all of their locations, a total of nearly 500 stores in 44 States and Puerto Rico.

The published goal for Burlington Coat Factory is to top the $15 million mark. In addition to their balloon icon program, Burlington also takes part in the LLS program 'Light The Night' Walks, which bring together communities for an evening walk to honor those people touched by blood cancers over the years.

"I am consistently impressed and overwhelmed by the tremendous generosity of our employees and our customers to give back in support of this important life-changing research," said Burlington Coat Factory president and chief executive officer Thomas Kingsbury. "We are looking forward to another outstanding campaign this season as we work together to raise funds in the fight against cancer."

Source: MarketWatch

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap